Glaukos Corporation (GKOS) Earnings Call Analysis

NYSE · Healthcare · Medical Devices

19/25

Growth 5 Margin 4 Expansion 4 Platform 1 Financial 5

latest quarter score

Earnings Reports

19
Glaukos (GKOS) Q2 2026: Epioxa Drives 90bps Gross Margin Gain as Launch Momentum Builds
July 30, 2026
20
Glaukos (GKOS) Q1 2026: iDoseTR Drives 58% U.S. Glaucoma Surge, Epioxa Launch Expands Access
April 30, 2026
17
Glaukos (GKOS) Q4 2025: iDose-TR Drives 53% U.S. Glaucoma Growth, Epioxa Launch Sets Up 2H Surge
February 24, 2026
17
GKOS Q3 2025: Epioxa Approval Sets $78K Rare Disease Pricing, Anchoring 2026 Growth Outlook
October 29, 2025
18
Glaukos (GKOS) Q2 2025: iDose TR Drives 45% U.S. Glaucoma Growth, Reshaping Ophthalmology Playbook
July 30, 2025
17
Glaukos (GKOS) Q1 2025: iDose-TR Drives 41% U.S. Glaucoma Growth, Offsetting Stent Declines
July 04, 2025

Browse all companies